|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.1 CAD | +1.94% |
|
+1.94% | -22.22% |
| Apr. 17 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
| Apr. 17 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
NervGen Pharma Corp. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was CAD 22.38 million compared to CAD 20.72 million a year ago.
Basic loss per share from continuing operations was CAD 0.38 compared to CAD 0.39 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -22.22% | 106M | |
| +0.17% | 42.86B | |
| +10.92% | 42.74B | |
| +44.30% | 41.36B | |
| -6.20% | 27.68B | |
| +5.23% | 25.15B | |
| -24.79% | 18.63B | |
| +26.69% | 12.37B | |
| -3.13% | 11.92B | |
| +6.57% | 11.21B |
NERVGEN PHARMA CORP. 
